Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MINORE study of infant B-cell levels after potential in utero exposure to ocrelizumab
2021-000062-14Phase 4Active
- Sponsor
- Roche
- Start
- Jul 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ocrelizumab in multiple sclerosis (MS) and clinically isolated syndrome (CIS), sponsored by Roche. Primary endpoint: Proportion of infants with B-cell depletion at week 6 postpartum. Started Jul 2021; status: active.
02
Drugs
ocrelizumab
03
Conditions
multiple sclerosis (MS)clinically isolated syndrome (CIS)
Beyond the preview
Go deeper on 2021-000062-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000062-14.